Advanced MR Analytics (AMRA) has signed an agreement with musculoskeletal health firm Artialis that will allow Artialis to use AMRA's technology for clinical trials for musculoskeletal disorders, specifically sarcopenia.
Sarcopenia is the decline of muscle structure and function in the elderly. Although several biomarkers have been shown to help treat the disease, more specific biomarkers sensitive to skeletal muscle changes are needed to prevent it, develop new therapies, and monitor treatment efficacy. MRI data have been helpful for developing such biomarkers, AMRA said.
AMRA's technology translates images from a six-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements that can then be used to evaluate a patient's body composition, according to the firm.